

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Millendo Therapeutics, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professors Gary Hammer and Tom Kerppola are both employees of the University of Michigan (“University”), and are partial owners of Millendo Therapeutics, Inc. (formerly, Atterocor, Inc.). The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Gary Hammer, MD, PhD, a Professor of Adrenal Cancer, Internal Medicine, Molecular and Integrative Physiology, Cell and Developmental Biology and Director of the Center for Organogenesis, and Tom Kerppola, PhD, a Professor of Biological Chemistry, are the partial owners of the for-profit company called Millendo Therapeutics, Inc. (the “Company”). The Company wishes to fund a project entitled “Millendo Therapeutics Protocol ART-101-001 (adrenocortical carcinoma): Patient Stratification (Phase 1) (Amendment #2: Lerario Samples Testing Cluster on Clusters Analysis)” (ORSP# 17-PAF06342) in the Department of Internal Medicine – Metabolism, Endocrinology & Diabetes, under the direction of Dr. Hammer. The purpose of this project is to conduct sample testing to support the ATR-101-001 protocol.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately two (2) years. The amount of funding support will not exceed \$74,385. Since research projects are often amended, this agreement includes a provision for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Hammer to use his expertise and University laboratory, as well as other University resources, for the ART-101-001 clinical protocol.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Millendo Therapeutics, Inc.

Respectfully submitted,

A handwritten signature in blue ink, appearing to read 'S. Jack Hu', is positioned above the printed name.

S. Jack Hu
Vice President for Research

April 2017